TEVA, US8816242098

Teva Pharmaceutical Industries stock: TD Cowen keeps Buy rating

Published on 11/16/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teva Pharmaceutical Industries stock drew a reiterated Buy rating from TD Cowen. The analyst set a USD 57 target, while TipRanks cited a Strong Buy consensus.

Analyst action and target

  • TD Cowen analyst Joseph Thome reiterated a Buy rating on Teva on November 12, 2026.
  • The analyst set a USD 57 price target, while TipRanks cited a Strong Buy consensus.
TEVA, US8816242098, Illustration mit AI erstellt.

TD Cowen analyst Joseph Thome reiterated a Buy rating on Teva on November 12, 2026, and set a USD 57 price target. Markets Insider reported the analyst action on November 13.

Target stands above consensus

The report cited a Strong Buy consensus on Teva and an average analyst target of USD 51.61. TD Cowen's USD 57 target therefore sits above that cited average, adding a more bullish individual view to the current analyst picture.

The analyst action follows Teva's third-quarter results and its updated growth narrative, including stronger innovative-medicine brands and pipeline investments. The company has also outlined a long-term ambition to generate USD 6 billion to USD 7 billion in innovative-medicines revenue by 2030.

Teva Pharmaceutical Industries Ltd.

  • Company: Teva Pharmaceutical Industries Ltd.
  • ISIN: US8816242098
  • Ticker: TEVA

U.S. equities provide the broader market setting for Teva stock through the S&P 500.

More news and analyses on Teva Pharmaceutical Industries stock

Disclaimer...
en | US8816242098 | TEVA | boerse | 70520236 | bgmi